Large Drugmakers Show Resilience Amid Industry Challenges

The drug and biotech sector has recovered in the past couple of months due to large drugmakers signing drug pricing agreements with the Trump administration. Despite headwinds like pipeline setbacks, patent cliffs, and regulatory risks, the industry's focus on innovation and positive pipeline/regulatory developments signal a favorable long-term outlook. Large drugmakers like Eli Lilly, Johnson & Johnson, and Sanofi have robust revenue streams and are mostly profitable, making them safe havens for long-term investment.